Inhaled Corticosteroids In Treatment of Cystic Fibrosis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Inhaled Corticosteroids In Treatment of Cystic Fibrosis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 11(3): 206-209.

Author(s): Ela Erdem and Refika Ersu.

Affiliation: Baglarbasi Cad. Toprak Sitesi C/Blok No, 90, Uskudar-Istanbul, Turkiye.


Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.


Inhaled corticosteroids, cystic fibrosis, adverse effects.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 3
First Page: 206
Last Page: 209
Page Count: 4
DOI: 10.2174/1871523011202030206
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science